Skip to main content

Table 4 Distributions used in the model

From: The value of using a brain laser interstitial thermal therapy (LITT) system in patients presenting with high grade gliomas where maximal safe resection may not be feasible

Type Name Description Param 1 Param 2 Param 3
Triangular Percent_major_complications_surgery Percent of patients experiencing a major complication from surgergy 0.045 0.09 0.13
Triangular Percent_major_complications_LITT Percent of major complications resulting from LITT procedure 0.0 0.027 0.06
Uniform Percent_GTR_biopsy Percentage of patients who have a GTR with biopsy 0.0 0.45  
Uniform Percent_major_complications_biopsy Percent of major complications resulting from stereotactic biopsy 0.031 0.064  
Uniform Percent_unresectable_rGBM_surgery Percent of recurrent GBMS that are unresectable with open craniotomy surgery 0.23 0.38  
Uniform Percent_open_resection_total Percent of eloquent areas of brain where a total resection was achieveable 0 0.23  
Uniform OS_EOR_biopsy Overall survival in months with biopsy based on an assumed extent of resection of <=70 % 4.85 12  
Triangular OS_EOR_STR Overall survival in months with Subtotal Resection biopsy or craniotomy based on an assumed extent of resection of >=85 % 9.7 10.9 12.2
Triangular OS_EOR_GTR Overall survival in months with Subtotal Resection biopsy or craniotomy based on an assumed extent of resection of >=98 % 11.4 13.1 14.6
Uniform Added_Survival_SRS Additional overall survival in months with use of SRS in patients who have a KPS >=70 7.5 8.5  
Uniform OS_recurrent_Diffuse_GBM Overall survival of recurrent diffuse GBM 6 7  
Normal PFS_LITT_GTR Progession free survival using LITT—assuming GTR 12.2 13.6  
Normal PFS_LITT_STR Progression free survival using LITT with subtotal resection 7.4 7  
Normal PFS_biopsy_GTR Progession free survival using biopsy with GTR 12.2 13.6  
Normal PFS_biopsy Progression free survival using biopsy with inadequate resection 4.8 5.2  
Normal PFS_surgery_GTR Progression free survival with surgery and GTR 12.2 13.6  
Normal PFS_surgery_STR Progression free survival with surgery with STR 7.4 7  
Normal LOS_surgery_GBM Average LOS and std dev for GBM procedures under DGR 26; 2012 data 6.55 1.77  
Uniform Timing_follow_on_chemo_TMZ Amount of time in days of follow on TMZ chemotherapy 180 360  
Normal Incremental_survival Incremental overall survival with implanting a carmustine wafer versus not 3.3 4.467  
Triangular Percent_neuro_comps_0_to_3_mths_surgery Percent of neurological complications (motor and cognitive lasting 0–3 months requiring rehabilitation; independent of major complications =>4 months 0.06 0.068 0.153
Uniform Percent_neuro_comps_0_to_3_mths_LITT Percent of neurological complicaitons (motor and cognitive lasting 0–3 months requiring rehabilitation; independent of major complications =>4 months 0 0.02  
Uniform Percent_Gliadel_wafer_implantations Percent of time a Gliadel wafer implanted in a patient for treating brain cancer 0.1 0.33